E-pharmacophore based virtual screening for identification of dual specific PDE5A and PDE3A inhibitors as potential leads against cardiovascular diseases

References

• Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D., & Manganiello, V. (2015). Cyclic nucleotide phosphodiesterases: Important signaling modulators and therapeutic targets. Oral Diseases, 21(1), e25–e50. doi:10.1111/odi.12275
   PubMed Web of Science ®Google Scholar
• Beavo, J. A., & Brunton, L. L. (2002). Cyclic nucleotide research – Still expanding after half a century. Nature Reviews Molecular Cell Biology, 3(9), 710–717. doi:10.1038/nrm911
   PubMed Web of Science ®Google Scholar
• Bento, A. P., Gaulton, A., Hersey, A., Bellis, L. J., Chambers, J., Davies, M., Krüger, F. A., Light, Y., Mak, L., McGlinchey, S., Nowotka, M., Papadatos, G., Santos, R., & Overington, J. P. (2014). The ChEMBL bioactivity database: An update. Nucleic Acids Research, 42(D1), D1083–D1090. doi:10.1093/nar/gkt1031
   PubMed Web of Science ®Google Scholar
• Bhatia, M. S., & Sherikar, A. S. (2017). Investigation of phosphodiesterase 5A (PDE5A) inhibitors by pharmacophore modeling, virtual screening and molecular docking approach. Journal of Applied Pharmaceutical Science, 7(9), 38–43. doi:10.7324/JAPS.2017.70905
   Google Scholar
• Bobin, P., Belacel-Ouari, M., Bedioune, I., Zhang, L., Leroy, J., Leblais, V., Fischmeister, R., & Vandecasteele, G. (2016). Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. Archives of Cardiovascular Diseases, 109(6–7), 431–443. doi:10.1016/j.acvd.2016.02.004
   PubMed Web of Science ®Google Scholar
• Boswell-Smith, V., Spina, D., & Page, C. P. (2006). Phosphodiesterase inhibitors. British Journal of Pharmacology, 147(S1), S252–S257. doi:10.1038/sj.bjp.0706495
   PubMed Web of Science ®Google Scholar
• Braga, R. C., & Andrade, C. H. (2013). Assessing the performance of 3D pharmacophore models in virtual screening: How good are they? Current Topics in Medicinal Chemistry, 13(9), 1127–1138. doi:10.2174/1568026611313090010
   PubMed Web of Science ®Google Scholar
• Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P. N., Artis, D. R., Bollag, G., Milburn, M. V., Kim, S.-H., Schlessinger, J., & Zhang, K. Y. J. (2004). Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure, 12(12), 2233–2247. doi:10.1016/j.str.2004.10.004
   PubMed Web of Science ®Google Scholar
• Cesarini, V., Pisano, C., Rossi, G., Balistreri, C. R., Botti, F., Antonelli, G., Ruvolo, G., Jannini, E. A., & Dolci, S. (2019). Regulation of PDE5 expression in human aorta and thoracic aortic aneurysms. Scientific Reports, 9(1), 12206. doi:10.1038/s41598-019-48432-6
   PubMed Web of Science ®Google Scholar
• Chan, S., & Yan, C. (2011). PDE1 isozymes, key regulators of pathological vascular remodeling. Current Opinion in Pharmacology, 11(6), 720–724. doi:10.1016/j.coph.2011.09.002
   PubMed Web of Science ®Google Scholar
• Crosswhite, P., & Sun, Z. (2010). Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. Journal of Hypertension, 28(2), 201.
   PubMed Web of Science ®Google Scholar
• da Silva, V. B., Kawano, D. F., Gomes, A. D. S., Carvalho, I., Taft, C. A., & da Silva, C. H. T. D. P. (2008). Molecular dynamics, density functional, ADMET predictions, virtual screening, and molecular interaction field studies for identification and evaluation of novel potential CDK2 inhibitors in cancer therapy. The Journal of Physical Chemistry A, 112(38), 8902–8910. doi:10.1021/jp8011969
   PubMed Web of Science ®Google Scholar
• Del Rio, A., Barbosa, A. J. M., Caporuscio, F., & Mangiatordi, G. F. (2010). CoCoCo: A free suite of multiconformational chemical databases for high-throughput virtual screening purposes. Molecular Biosystems, 6(11), 2122–2128. doi:10.1039/c0mb00039f
   PubMedGoogle Scholar
• Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20(10–11), 647–671. doi:10.1007/s10822-006-9087-6
   PubMed Web of Science ®Google Scholar
• Dror, O., Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2009). Novel approach for efficient pharmacophore-based virtual screening: Method and applications. Journal of Chemical Information and Modeling, 49(10), 2333–2343. doi:10.1021/ci900263d
   PubMed Web of Science ®Google Scholar
• Ece, A. (2016). e-Pharmacophore mapping combined with virtual screening and molecular docking to identify potent and selective inhibitors of P90 ribosomal S6 kinase (RSK).
   Google Scholar
• Ece, A. (2020). Towards more effective acetylcholinesterase inhibitors: A comprehensive modelling study based on human acetylcholinesterase protein–drug complex. Journal of Biomolecular Structure and Dynamics, 38(2), 565–568. doi:10.1080/07391102.2019.1583606
   PubMed Web of Science ®Google Scholar
• Ece, A., & Sevin, F. (2013). The discovery of potential cyclin A/CDK2 inhibitors: A combination of 3D QSAR pharmacophore modeling, virtual screening, and molecular docking studies. Medicinal Chemistry Research, 22(12), 5832–5843.
   Web of Science ®Google Scholar
• Feil, R., Lohmann, S. M., de Jonge, H., Walter, U., & Hofmann, F. (2003). Cyclic GMP-dependent protein kinases and the cardiovascular system: Insights from genetically modified mice. Circulation Research, 93(10), 907–916. doi:10.1161/01.RES.0000100390.68771.CC
   PubMed Web of Science ®Google Scholar
• Fischmeister, R., Castro, L. R. V., Abi-Gerges, A., Rochais, F., JurevičIus, J., Leroy, J., & Vandecasteele, G. (2006). Compartmentation of cyclic nucleotide signaling in the heart: The role of cyclic nucleotide phosphodiesterases. Circulation Research, 99(8), 816–828. doi:10.1161/01.RES.0000246118.98832.04
   PubMed Web of Science ®Google Scholar
• Foresta, C., Caretta, N., Zuccarello, D., Poletti, A., Biagioli, A., Caretti, L., & Galan, A. (2008). Expression of the PDE5 enzyme on human retinal tissue: New aspects of PDE5 inhibitors ocular side effects. Eye, 22(1), 144–149. p doi:10.1038/sj.eye.6702908
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. doi:10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. doi:10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. doi:10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Ghosh, S., Liu, X., Zheng, Y., & Uckun, F. M. (2001). Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Current Cancer Drug Targets, 1(2), 129–140. doi:10.2174/1568009013334188
   PubMed Web of Science ®Google Scholar
• Greco, E. A., Spera, G., & Aversa, A. (2006). Combining testosterone and PDE5 inhibitors in erectile dysfunction: Basic rationale and clinical evidences. European Urology, 50(5), 940–947. doi:10.1016/j.eururo.2006.06.049
   PubMed Web of Science ®Google Scholar
• Greenwood, J. R., Calkins, D., Sullivan, A. P., & Shelley, J. C. (2010). Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. Journal of Computer-Aided Molecular Design, 24(6–7), 591–604. doi:10.1007/s10822-010-9349-1
   PubMed Web of Science ®Google Scholar
• Gresele, P., Momi, S., & Falcinelli, E. (2011). Anti-platelet therapy: Phosphodiesterase inhibitors. British Journal of Clinical Pharmacology, 72(4), 634–646. doi:10.1111/j.1365-2125.2011.04034.x
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759. doi:10.1021/jm030644s
   PubMed Web of Science ®Google Scholar
• Hambleton, R., Krall, J., Tikishvili, E., Honeggar, M., Ahmad, F., Manganiello, V. C., & Movsesian, M. A. (2005). Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. Journal of Biological Chemistry, 280(47), 39168–39174. doi:10.1074/jbc.M506760200
   PubMed Web of Science ®Google Scholar
• Hashmi, S. K., Afridi, M. B., Abbas, K., Sajwani, R. A., Saleheen, D., Frossard, P. M., Ishaq, M., Ambreen, A., & Ahmad, U. (2007). Factors associated with adherence to anti-hypertensive treatment in Pakistan. PLoS One, 2(3), e280. doi:10.1371/journal.pone.0000280
   PubMed Web of Science ®Google Scholar
• Hillisch, A., Pineda, L. F., & Hilgenfeld, R. (2004). Utility of homology models in the drug discovery process. Drug Discovery Today., 9(15), 659–669. doi:10.1016/S1359-6446(04)03196-4
   PubMed Web of Science ®Google Scholar
• Honma, T., Hayashi, K., Aoyama, T., Hashimoto, N., Machida, T., Fukasawa, K., Iwama, T., Ikeura, C., Ikuta, M., Suzuki-Takahashi, I., Iwasawa, Y., Hayama, T., Nishimura, S., & Morishima, H. (2001). Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design. Journal of Medicinal Chemistry, 44(26), 4615–4627. doi:10.1021/jm0103256
   PubMed Web of Science ®Google Scholar
• Huang, N., Shoichet, B. K., & Irwin, J. J. (2006). Benchmarking sets for molecular docking. Journal of Medicinal Chemistry, 49(23), 6789–6801. doi:10.1021/jm0608356
   PubMed Web of Science ®Google Scholar
• Huang, Z., & Wong, C. F. (2016). Inexpensive method for selecting receptor structures for virtual screening. Journal of Chemical Information and Modeling, 56(1), 21–34. doi:10.1021/acs.jcim.5b00299
   PubMed Web of Science ®Google Scholar
• Ikeda, Y. (1999). Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thrombosis and Haemostasis, 82(8), 435–438. doi:10.1055/s-0037-1615863
   PubMed Web of Science ®Google Scholar
• Irwin, J. J., & Shoichet, B. K. (2005). ZINC – A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling, 45(1), 177–182.
   PubMed Web of Science ®Google Scholar
• Jacobson, M. P., Friesner, R. A., Xiang, Z., & Honig, B. (2002). On the role of the crystal environment in determining protein side-chain conformations. Journal of Molecular Biology, 320(3), 597–608. doi:10.1016/S0022-2836(02)00470-9
   PubMed Web of Science ®Google Scholar
• Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J., Honig, B., Shaw, D. E., & Friesner, R. A. (2004). A hierarchical approach to all-atom protein loop prediction. Proteins: Structure, Function, and Bioinformatics, 55(2), 351–367. doi:10.1002/prot.10613
   PubMed Web of Science ®Google Scholar
• Kaptoge, S., Pennells, L., De Bacquer, D., Cooney, M. T., Kavousi, M., Stevens, G., Riley, L. M., Savin, S., Khan, T., Altay, S., Amouyel, P., Assmann, G., Bell, S., Ben-Shlomo, Y., Berkman, L., Beulens, J. W., Björkelund, C., Blaha, M., Blazer, D. G., … Di Angelantonio, E. (2019). World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. The Lancet Global Health, 7(10), e1332–e1345. doi:10.1016/S2214-109X(19)30318-3
   PubMed Web of Science ®Google Scholar
• Kawatkar, S., Wang, H., Czerminski, R., & Joseph-McCarthy, D. (2009). Virtual fragment screening: An exploration of various docking and scoring protocols for fragments using Glide. Journal of Computer-Aided Molecular Design, 23(8), 527–539. doi:10.1007/s10822-009-9281-4
   PubMed Web of Science ®Google Scholar
• Khalid, R. R., Maryam, A., Fadouloglou, V. E., Siddiqi, A. R., & Zhang, Y. (2019). Cryo-EM density map fitting driven in-silico structure of human soluble guanylate cyclase (hsGC) reveals functional aspects of inter-domain cross talk upon NO binding. Journal of Molecular Graphics and Modelling, 90, 109–119. doi:10.1016/j.jmgm.2019.04.009
   PubMed Web of Science ®Google Scholar
• Koyama, H., Bornfeldt, K. E., Fukumoto, S., & Nishizawa, Y. (2001). Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. Journal of Cellular Physiology, 186(1), 1–10. doi:10.1002/1097-4652(200101)186:1<1::AID-JCP1012>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead-and drug-like compounds: The rule-of-five revolution. Drug Discovery Today: Technologies, 1(4), 337–341. doi:10.1016/j.ddtec.2004.11.007
   PubMedGoogle Scholar
• Lovell, S., Davis, I., Arendall, W., III, Bakker, P. I. W., Word, J. M., Prisant, M. G., Richardson, J. S., & Richardson, D. C. (2003). Structure validation by Ca geometry: F, C and Cb deviation. Proteins: Structure, Function, and Bioinformatics, 50(3), 437–450. doi:10.1002/prot.10286
   PubMed Web of Science ®Google Scholar
• Loving, K., Salam, N. K., & Sherman, W. (2009). Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. Journal of Computer-Aided Molecular Design, 23(8), 541–554. doi:10.1007/s10822-009-9268-1
   PubMed Web of Science ®Google Scholar
• Madden, T. (2013). The BLAST sequence analysis tool. In The NCBI handbook [Internet] (2nd ed.). National Center for Biotechnology Information (US).
   Google Scholar
• Mahajan, S., Ghosh, S., Sudbeck, E. A., Zheng, Y., Downs, S., Hupke, M., & Uckun, F. M. (1999). Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide]. Journal of Biological Chemistry, 274(14), 9587–9599. doi:10.1074/jbc.274.14.9587
   PubMed Web of Science ®Google Scholar
• Mantsyzov, A. B., Bouvier, G., Evrard-Todeschi, N., & Bertho, G. (2012). Contact-based ligand-clustering approach for the identification of active compounds in virtual screening. Advances and Applications in Bioinformatics and Chemistry: AABC, 5, 61.
   PubMedGoogle Scholar
• Maryam, A., Vedithi, S. C., Khalid, R. R., Alsulami, A. F., Torres, P. H. M., Siddiqi, A. R., & Blundell, T. L. (2019). The molecular organization of human cGMP specific phosphodiesterase 6 (PDE6): Structural implications of somatic mutations in cancer and retinitis pigmentosa. Computational and Structural Biotechnology Journal, 17, 378–389. doi:10.1016/j.csbj.2019.03.004
   PubMed Web of Science ®Google Scholar
• Maurice, D. H. (2005). Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Frontiers in Bioscience, 10(1–3), 1221–1228. doi:10.2741/1614
   PubMed Web of Science ®Google Scholar
• Maurice, D. H., Palmer, D., Tilley, D. G., Dunkerley, H. A., Netherton, S. J., Raymond, D. R., Elbatarny, H. S., & Jimmo, S. L. (2003). Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Molecular Pharmacology, 64(3), 533–546. doi:10.1124/mol.64.3.533
   PubMed Web of Science ®Google Scholar
• Mollica, A., Zengin, G., Durdagi, S., Ekhteiari Salmas, R., Macedonio, G., Stefanucci, A., Dimmito, M. P., & Novellino, E. (2019). Combinatorial peptide library screening for discovery of diverse α-glucosidase inhibitors using molecular dynamics simulations and binary QSAR models. Journal of Biomolecular Structure and Dynamics, 37(3), 726–740. doi:10.1080/07391102.2018.1439403
   PubMed Web of Science ®Google Scholar
• Movsesian, M. (2003). Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases. Google Patents.
   Google Scholar
• Movsesian, M. A. (2002). PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signalling in cardiac myocytes. Basic Research in Cardiology, 97(7), 1–I90. doi:10.1007/s003950200035
   PubMed Web of Science ®Google Scholar
• Movsesian, M. A., & Kukreja, R. C. (2011). Phosphodiesterase inhibition in heart failure. In S. Francis, M. Conti, & M. Houslay (Eds.), Phosphodiesterases as drug targets (pp. 237–249). Springer.
   Google Scholar
• Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012). Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking. Journal of Medicinal Chemistry, 55(14), 6582–6594. doi:10.1021/jm300687e
   PubMed Web of Science ®Google Scholar
• Nankervis, J. L., Feil, S. C., Hancock, N. C., Zheng, Z., Ng, H.-L., Morton, C. J., Holien, J. K., Ho, P. W. M., Frazzetto, M. M., Jennings, I. G., Manallack, D. T., John Martin, T., Thompson, P. E., & Parker, M. W. (2011). Thiophene inhibitors of PDE4: Crystal structures show a second binding mode at the catalytic domain of PDE4D2. Bioorganic and Medicinal Chemistry Letters, 21(23), 7089–7093. doi:10.1016/j.bmcl.2011.09.109
   PubMed Web of Science ®Google Scholar
• Poli, G., Dimmito, M. P., Mollica, A., Zengin, G., Benyhe, S., Zador, F., & Stefanucci, A. (2019). Discovery of novel µ-opioid receptor inverse agonist from a combinatorial library of tetrapeptides through structure-based virtual screening. Molecules, 24(21), 3872. doi:10.3390/molecules24213872
   Web of Science ®Google Scholar
• Prabhu, S. V., & Singh, S. K. (2019). Energetically optimized pharmacophore modeling to identify dual negative allosteric modulators against group I mGluRs in neurodegenerative diseases. Journal of Biomolecular Structure and Dynamics, 1–12. doi:10.1080/07391102.2019.1640794
   Web of Science ®Google Scholar
• Rabe, K., Magnussen, H., & Dent, G. (1995). Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. European Respiratory Journal, 8(4), 637–642.
   PubMed Web of Science ®Google Scholar
• Rosengren, A., Smyth, A., Rangarajan, S., Ramasundarahettige, C., Bangdiwala, S. I., AlHabib, K. F., Avezum, A., Bengtsson Boström, K., Chifamba, J., Gulec, S., Gupta, R., Igumbor, E. U., Iqbal, R., Ismail, N., Joseph, P., Kaur, M., Khatib, R., Kruger, I. M., Lamelas, P., … Yusuf, S. (2019). Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: The Prospective Urban Rural Epidemiologic (PURE) study. The Lancet Global Health, 7(6), e748–e760. doi:10.1016/S2214-109X(19)30045-2
   PubMed Web of Science ®Google Scholar
• Roth, G. A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S. F., Abyu, G., Ahmed, M., Aksut, B., Alam, T., Alam, K., Alla, F., Alvis-Guzman, N., Amrock, S., Ansari, H., Ärnlöv, J., Asayesh, H., Atey, T. M., Avila-Burgos, L., Awasthi, A., … Murray, C. (2017). Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. Journal of the American College of Cardiology, 70(1), 1–25. doi:10.1016/j.jacc.2017.04.052
   PubMed Web of Science ®Google Scholar
• Salam, N. K., Nuti, R., & Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. Journal of Chemical Information and Modeling, 49(10), 2356–2368.
   PubMed Web of Science ®Google Scholar
• Sampson, L., Hinton, J., & Garland, C. (2001). Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries. British Journal of Pharmacology, 132(1), 13–17. doi:10.1038/sj.bjp.0703831
   PubMed Web of Science ®Google Scholar
• Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. doi:10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Saxena, S., Abdullah, M., Sriram, D., & Guruprasad, L. (2018). Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: Homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 36(12), 3184–3198. doi:10.1080/07391102.2017.1384398
   PubMed Web of Science ®Google Scholar
• Scapin, G., Patel, S. B., Chung, C., Varnerin, J. P., Edmondson, S. D., Mastracchio, A., Parmee, E. R., Singh, S. B., Becker, J. W., Van der Ploeg, L. H. T., & Tota, M. R. (2004). Crystal structure of human phosphodiesterase 3B: Atomic basis for substrate and inhibitor specificity. Biochemistry, 43(20), 6091–6100. doi:10.1021/bi049868i
   PubMed Web of Science ®Google Scholar
• Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. (2010). Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. Journal of Chemical Theory and Computation, 6(5), 1509–1519. doi:10.1021/ct900587b
   PubMed Web of Science ®Google Scholar
• Sindhikara, D., Spronk, S. A., Day, T., Borrelli, K., Cheney, D. L., & Posy, S. L. (2017). Improving accuracy, diversity, and speed with prime macrocycle conformational sampling. Journal of Chemical Information and Modeling, 57(8), 1881–1894. doi:10.1021/acs.jcim.7b00052
   PubMed Web of Science ®Google Scholar
• Stoclet, J.-C., Keravis, T., Komas, N., & Lugnier, C. (1995). Section review: Cardiovascular & renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Expert Opinion on Investigational Drugs, 4(11), 1081–1100. doi:10.1517/13543784.4.11.1081
   Google Scholar
• Truchon, J.-F., & Bayly, C. I. (2007). Evaluating virtual screening methods: Good and bad metrics for the “early recognition” problem. Journal of Chemical Information and Modeling, 47(2), 488–508. doi:10.1021/ci600426e
   PubMed Web of Science ®Google Scholar
• Tsai, L.-C L., & Beavo, J. A. (2011). The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Current Opinion in Pharmacology, 11(6), 670–675. doi:10.1016/j.coph.2011.09.003
   PubMed Web of Science ®Google Scholar
• ul Qamar, M. T., Maryam, A., Muneer, I., Xing, F., Ashfaq, U. A., Khan, F. A., Anwar, F., Geesi, M. H., Khalid, R. R., Rauf, S. A., & Siddiqi, A. R. (2019). Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus. Scientific Reports, 9(1), 1433. doi:10.1038/s41598-018-38450-1
   PubMed Web of Science ®Google Scholar
• UniProt: The universal protein knowledgebase. (2016). Nucleic Acids Research, 45(D1), D158–D169.
   PubMed Web of Science ®Google Scholar
• Vankayalapati, H., Bearss, D. J., Saldanha, J. W., Muñoz, R. M., Rojanala, S., Von Hoff, D. D., & Mahadevan, D. (2003). Targeting aurora2 kinase in oncogenesis: A structural bioinformatics approach to target validation and rational drug design. Molecular Cancer Therapeutics, 2(3), 283–294.
   PubMed Web of Science ®Google Scholar
• Villoutreix, B. O., Eudes, R., & Miteva, M. A. (2009). Structure-based virtual ligand screening: Recent success stories. Combinatorial Chemistry & High Throughput Screening, 12(10), 1000–1016. doi:10.2174/138620709789824682
   PubMed Web of Science ®Google Scholar
• Wang, G., Liu, Z., Chen, T., Wang, Z., Yang, H., Zheng, M., Ren, J., Tian, G., Yang, X., Li, L., Li, J., Suo, J., Zhang, R., Jiang, X., Terrett, N. K., Shen, J., Xu, Y., & Jiang, H. (2012). Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. Journal of Medicinal Chemistry, 55(23), 10540–10550. doi:10.1021/jm301159y
   PubMed Web of Science ®Google Scholar
• Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S. H., Corbin, J. D., Robinson, H., Xin, Z., Lin, G., & Ke, H. (2006). Multiple conformations of phosphodiesterase-5: Implications for enzyme function and drug development. Journal of Biological Chemistry, 281(30), 21469–21479. doi:10.1074/jbc.M512527200
   PubMed Web of Science ®Google Scholar
• Wang, H., Ye, M., Robinson, H., Francis, S. H., & Ke, H. (2008). Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Molecular Pharmacology, 73(1), 104–110. doi:10.1124/mol.107.040212
   PubMed Web of Science ®Google Scholar
• Wharton, J., Strange, J. W., Møller, G. M. O., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C., & Wilkins, M. R. (2005). Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. American Journal of Respiratory and Critical Care Medicine, 172(1), 105–113. doi:10.1164/rccm.200411-1587OC
   PubMed Web of Science ®Google Scholar
• Wobst, J., Kessler, T., Dang, T. A., Erdmann, J., & Schunkert, H. (2015). Role of sGC-dependent NO signalling and myocardial infarction risk. Journal of Molecular Medicine, 93(4), 383–394. doi:10.1007/s00109-015-1265-3
   PubMed Web of Science ®Google Scholar
• Workbench, C. G. v3.6. (2010). Now new version can be available at http://www.clcbio.com/products/clcgenomicsworkbench
   Google Scholar
• Zhang, W., & Colman, R. W. (2000). Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding. Blood, 95(11), 3380–3386. doi:10.1182/blood.V95.11.3380.011k25_3380_3386
   PubMed Web of Science ®Google Scholar
• Zhang, W., Ke, H., & Colman, R. (2002). Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Molecular Pharmacology, 62(3), 514–520. doi:10.1124/mol.62.3.514
   PubMed Web of Science ®Google Scholar
• Zhang, W., Ke, H., Tretiakova, A. P., Jameson, B., & Colman, R. W. (2001). Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B. Protein Science, 10(8), 1481–1489. doi:10.1110/ps.6601
   PubMed Web of Science ®Google Scholar